| First Author | Kaufmann E | Year | 2022 |
| Journal | Cell Rep | Volume | 38 |
| Issue | 10 | Pages | 110502 |
| PubMed ID | 35235831 | Mgi Jnum | J:335954 |
| Mgi Id | MGI:7286276 | Doi | 10.1016/j.celrep.2022.110502 |
| Citation | Kaufmann E, et al. (2022) BCG vaccination provides protection against IAV but not SARS-CoV-2. Cell Rep 38(10):110502 |
| abstractText | Since the vast majority of species solely rely on innate immunity for host defense, it stands to reason that a critical evolutionary trait like immunological memory evolved in this primitive branch of our immune system. There is ample evidence that vaccines such as bacillus Calmette-Guerin (BCG) induce protective innate immune memory responses (trained immunity) against heterologous pathogens. Here we show that while BCG vaccination significantly reduces morbidity and mortality against influenza A virus (IAV), it fails to provide protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In contrast to IAV, SARS-CoV-2 infection leads to unique pulmonary vasculature damage facilitating viral dissemination to other organs, including the bone marrow (BM), a central site for BCG-mediated trained immunity. Finally, monocytes from BCG-vaccinated individuals mount an efficient cytokine response to IAV infection, while this response is minimal following SARS-CoV-2. Collectively, our data suggest that the protective capacity of BCG vaccination is contingent on viral pathogenesis and tissue tropism. |
